Today's Daily Dose brings you news about progress on BeiGene's investigational Bruton's tyrosine kinase inhibitor Zanubrutinib; FDA approval of Bausch Health's topical treatment of acne vulgaris and Zai Lab's discontinuation of its atopic dermatitis therapy.
from RTT - Biotech https://ift.tt/2obWLIk
via IFTTT
No comments:
Post a Comment